NCT02535247 · OUTCOME

Overall Survival

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma · Source last updated 2022-07-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 6 Months

Analysis population: Study did not progress to portion with combination of pembrolizumab and copanlisib

Groups in this outcome

Treatment

MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475

Combination

MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment	17
Combination	0

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment	3.2	Not reported	1.2	3.7	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1.2
upper Limit
3.7
value
3.2

denoms

counts
group Id
OG000
value
17
group Id
OG001
value
0
units
Participants

dispersion Type

95% Confidence Interval

groups

description
MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles MK-3475
id
OG000
title
Treatment
description
MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study MK-3475 Copanlisib
id
OG001
title
Combination

param Type

MEDIAN

population Description

Study did not progress to portion with combination of pembrolizumab and copanlisib

reporting Status

POSTED

time Frame

6 Months

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice